This further support a protective role for adiponectin in AD, suggesting that diminished brain adiponectin signaling in obesity may favor AD onset and progression and that adiponectin signaling may be an interesting target in AD therapy. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.